Navigation Links
Neurocrine Biosciences Reports Second Quarter 2009 Results
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended June 30, 2009. For the second quarter of 2009, the Company reported a net loss of $15.3 million, or $0.39 per share, compared with a net loss of $21.0 million, or $0.55 per share, for the same period in 2008. For the six months ended June 30, 2009, the Company reported a net loss of $34.9 million, or $0.90 per share, as compared to $42.0 million, or $1.10 per share, for the same period last year.

Revenues for the second quarter of 2009 and 2008 were $0.7 million. Revenues for the six months ended June 30, 2009 were $1.5 million, compared with $2.5 million for the same period in 2008. The decrease in revenues is primarily due to milestones recognized in 2008 under our collaboration agreement with GlaxoSmithKline (GSK) related to the clinical advancements of our CRF program. During both six month periods ended June 30, 2009 and 2008, we recognized $1.5 million in revenue under our collaboration agreement for indiplon with Dainippon Sumitomo Pharma Co. Ltd. (DSP) from amortization of up-front licensing fees.

Research and development expenses decreased to $10.8 million during the second quarter of 2009 compared with $16.2 million for the same period in 2008. For the six months ended June 30, 2009, research and development expenses were $21.7 million, compared to $30.4 million for the same period last year. The decrease in research and development expenses is primarily due to expense management efforts and decreasing external clinical development expenses related to the elagolix program.

General and administrative expenses were $4.8 million for the second quarter of 2009 and $4.7 million during the same period last year. For t
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
3. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
4. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
5. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
8. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
9. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.502 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
... Plasmid , Mini Kit , ... James Griffith and Kim Vollmer , James Griffith, ... Instruments, Biosytems Application Lab, Westbury, , NY , , ... , Cosmids are commonly used vectors in the lab, providing the ...
... , , , , Other important parameters for optimizing electroporation., , , , ... , , Pulse length , ... field pulses , Adjustment , of ... , Influence , of temperature , ...
Cached Biology Technology:Agrobacterium tumefaciens 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 3Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 4Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 5
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... SALT LAKE CITY A single organ may contain more ... that complicates prospects for using the versatile cells to replace ... new study from the laboratory of geneticist Mario Capecchi, the ... online issue of the journal Nature Genetics, Capecchi and geneticist ...
... challenges is to understand the design principles and origins ... on the evolutionary origins of the brain and how ... humans. The research suggests that it is not ... during evolution, increasingly sophisticated molecular processing of nerve impulses ...
... Communication,Intelligence Corporation (the "Company") (OTC Bulletin Board: ... business process,automation in the financial industry and the ... it has closed a financing, on,June 5, 2008, ... As part of the financing, the Company ...
Cached Biology News:Caution on stem cell therapy 2Caution on stem cell therapy 3Caution on stem cell therapy 4Origins of the brain 2Origins of the brain 3Communication Intelligence Corporation Closes $3.6 Million Financing 2Communication Intelligence Corporation Closes $3.6 Million Financing 3Communication Intelligence Corporation Closes $3.6 Million Financing 4
For microscopy...
... cDNA Synthesis and Labeling Kit generates labeled ... First unmodified cDNA is made via a ... an Oligo(dT) primer. Unlike other methods, there ... the reverse transcription reaction. This unmodified cDNA ...
... high quality microarray scanner based on patented confocal ... spatial resolution. The DNAscope LM is unique ... scanner that is upgradeable to a total of ... Includes control module (computer), monitor, and ...
AC input: 50-60 Hz 115-120 V...
Biology Products: